New targets for antimalarial therapy: the plasmepsins, malaria parasite aspartic proteinases

Berry, Colin ORCID: https://orcid.org/0000-0002-9943-548X 1997. New targets for antimalarial therapy: the plasmepsins, malaria parasite aspartic proteinases. Biochemical Education 25 (4) , pp. 191-194. 10.1016/S0307-4412(97)00130-1

Full text not available from this repository.

Abstract

Chloroquine has formed the basis of much malaria control for the last 40 years but with the recent increases in the resistance of malaria parasites to such antimalarial agents, there is a great need for immediate development of new antimalarial agents. The Plasmodium aspartic proteinases perform a crucial role in the provision of nutrients for the red cell stages of the malaria parasite and thus make excellent drug targets. Inhibition of aspartic proteinases has been shown to kill parasites in human red blood cells in culture. In P falciparum, two aspartic proteinases, plasmepsin I and plasmepsin II are produced but they are distinct in the times at which they are produced in the erythrocytic stages of growth, their specificities and their susceptibility to inhibitors. Several compounds identified to date by in vivo screening are selective for inhibition of plasmepsin I which appears to be a key drug target in P falciparum.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Subjects:	Q Science > QR Microbiology
Publisher:	Elsevier
ISSN:	0307-4412
Last Modified:	27 Oct 2022 09:13
URI:	https://orca.cardiff.ac.uk/id/eprint/64821

Citation Data

Cited 9 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item